Skin Aging Clinical Trial
Official title:
The Role of Red Flavonoid in Photoaging
The goal of this clinical trial is to learn about the effects of "red flavonoid" substance on skin, which is extracted from a plant called Camellia japonica, in adults aged of 45 or older with photo-damaged skin. The main questions it aims to answer are: - Does red flavonoid have an anti-aging effect? - Does red flavonoid have any skin quality-improving effects? Participants will - Be using creams with or without red flavonoid (only moisturizing creams) and sun-screen for the duration of the study. - Get a skin biopsy before and after using the creams. - Be taken photos of the face and neck region and have a skin examination at each visit. - Complete a self-questionnaire at final visit. Researchers will compare the group who uses red flavonoid facial cream with the group who uses moisturizing cream to see if red flavonoid has an effect on appearance and structure.
The purpose of this study is to investigate the anti-photoaging effects of red flavonoid, a product with natural phytochemical kaempferol tetrasaccharides (KTs) extracted from Camellia japonica. The investigators hypothesize that Red flavonoids extracted from Camellia japonica will present anti-aging effects, such as skin smoothening, increased elasticity, and brightening, with high subjective participant satisfaction and microscopically corroborating analyses. Individuals will be recruited from patient populations seen at the general dermatology clinics of Johns Hopkins Department of Dermatology or from patient populations participating in Johns Hopkins Cutaneous Translational Research Program (CTReP) research studies. Study procedures will be conducted at the Johns Hopkins CTReP office located at the Johns Hopkins Outpatient Center. Once eligibility has been demonstrated, the potential subjects will be instructed to make the first study appointment. This feasibility study will have a study population of up to 75 individuals over the age of 45. Each study participant will have up to 7 on-site visits within 24 weeks. A facial cream with or without 0.1% red flavonoid will be provided for twice-daily use. At various time points, photographs and clinical assessments will be collected as well as punch biopsy samples for laboratory study. At the discretion of the principal investigator, biopsies may be taken from subjects before and following daily usage of the product of interest, up to 8 biopsies in total. The timepoints may be adjusted as data is being collected. A punch biopsy procedure will be employed which is a routine dermatological procedure consisting of local anesthesia, followed by the punch, which cuts a cylindrical core of epidermis, dermis, and subcutaneous tissue. A biopsy size of up to 4-mm in diameter is considered enough to perform all tests required by this protocol. After removal of the tissue sample, a suture is placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin. Standardized digital photographs will be obtained by study staff using a digital camera and software under standard photographic conditions at each study visit. Participants' eyes will be blacked out to de-identify photos. Photograph files will be coded to remove personal identifiers and stored on a secure hard drive in CTReP. Non-invasive clinical assessments will be performed to 1) record skin findings using graded scales if needed, 2) to identify suitable areas for biopsy, 3) give information/demonstration about the product of interest, 4) to identify occurrence of any adverse events and 5) record post treatment findings. Tissue work-up may include, but not limited to hematoxylin and eosin staining for assessment of epidermal/dermal thickness, reverse transcription-polymerase chain reaction and immunohistochemistry for photoaging and pigmentation markers such as fibrillin-1, collagen type IV, or collagen type I, and tyrosinase. Any clinical findings determined by the Investigator to be important and/or unusual will be referred to as an adverse event. Study participants are asked to contact clinic staff immediately if the participants experience a reaction to the topical applications at any time during the study. Expected reactions may be documented in a problem events log. The investigator will use his discretion to remove participants from the study, and all problem events will be reported to Institutional Review Board. Differences in protein expression between the test sites, and after application of test substances for varying periods of time, will be assessed for significance using either Student's t-test or analysis of variance (or non-parametric equivalents, if necessary) depending on the comparison required. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04276753 -
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
|
N/A | |
Completed |
NCT06125912 -
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
|
N/A | |
Completed |
NCT02580370 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
|
Phase 3 | |
Recruiting |
NCT01583478 -
Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
|
Phase 4 | |
Completed |
NCT02003833 -
Poly-L-lactic Acid for Skin Quality
|
Phase 4 | |
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00986570 -
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
|
Phase 3 | |
Completed |
NCT00974480 -
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
|
N/A | |
Completed |
NCT00272610 -
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
|
Phase 2 | |
Recruiting |
NCT03730649 -
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
|
Early Phase 1 | |
Completed |
NCT03312543 -
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
|
N/A | |
Active, not recruiting |
NCT05349799 -
TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines
|
N/A | |
Completed |
NCT03677258 -
Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy
|
N/A | |
Completed |
NCT01981980 -
Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT00767156 -
Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
|
N/A | |
Recruiting |
NCT05813054 -
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
|
N/A | |
Not yet recruiting |
NCT04485091 -
TCA Peel and Photobiomodulation for Hand Rejuvenation
|
Phase 2 | |
Completed |
NCT05457491 -
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
|
Phase 1 | |
Completed |
NCT01237977 -
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
|
Phase 3 | |
Completed |
NCT01029301 -
Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas
|
N/A |